Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

por Zhang, Baoshan, Gorman, Jason, Kwon, Young D., Pegu, Amarendra, Chao, Cara W., Liu, Tracy, Asokan, Mangaiarkarasi, Bender, Michael F., Bylund, Tatsiana, Damron, Leland, Gollapudi, Deepika, Lei, Paula, Li, Yile, Liu, Cuiping, Louder, Mark K., McKee, Krisha, Olia, Adam S., Rawi, Reda, Schön, Arne, Wang, Shuishu, Yang, Eun Sung, Yang, Yongping, Carlton, Kevin, Doria-Rose, Nicole A., Shapiro, Lawrence, Seaman, Michael S., Mascola, John R., Kwong, Peter D.
Publicado 2023

Engineering of HIV-1 neutralizing antibody CAP256V2LS for manufacturability and improved half life

por Zhang, Baoshan, Gollapudi, Deepika, Gorman, Jason, O’Dell, Sijy, Damron, Leland F., McKee, Krisha, Asokan, Mangaiarkarasi, Yang, Eun Sung, Pegu, Amarendra, Lin, Bob C., Chao, Cara W., Chen, Xuejun, Gama, Lucio, Ivleva, Vera B., Law, William H., Liu, Cuiping, Louder, Mark K., Schmidt, Stephen D., Shen, Chen-Hsiang, Shi, Wei, Stein, Judith A., Seaman, Michael S., McDermott, Adrian B., Carlton, Kevin, Mascola, John R., Kwong, Peter D., Lei, Q. Paula, Doria-Rose, Nicole A.
Publicado 2022